Moderna, Merck cancer vaccine shows promise in late-stage trial; Moderna stock soars 50%

Merck's once-monthly HIV prevention pill, MK-8527, enters final testing. Early data from South Africa's six-monthly jab rollout suggests more prevention options could increase usage. Aspen Pharmacare, among others, receives licenses to produce generic versions, potentially lowering costs and improving access. Studies may conclude by late 2027.

Moderna (MRNA) surged 156.0% in August 2026 after promising mRNA cancer vaccine trial results. Its P/S ratio is 25.82, above historical and industry norms. GF Value™ suggests it's 503.4% overvalued. Insider selling totaled $48.3M in 12 months. GuruFocus GF Score™ is 62/100, indicating mixed fundamentals.

Dr. Michael Osterholm, director of the University of Minnesota's Center for Infectious Disease Research and Policy, discussed vaccine misinformation, cyclosporiasis outbreaks, and pandemic preparedness. His Vaccine Integrity Project, funded by Christy Walton, supports vaccine safety and outreach. Osterholm criticized federal vaccine policy changes and expressed concerns about pandemic readiness and mRNA vaccine acceptance. Moderna's FDA-approved mRNA flu vaccine was noted as a development.

Moderna and Merck's personalized mRNA cancer vaccine (mRNA-4157) met its primary endpoint in Phase 3 trials, boosting their market value by over $50 billion. The success highlights the role of sequencing companies like Tempus AI and Personalis, which provide genetic profiling for personalized vaccines. Tempus AI's planned acquisition of Personalis faces competition as Personalis' stock surpasses the offer price, sparking speculation of a bidding war. The deal's strategic value lies in Personalis

Moderna and Revolution Medicines reported significant advancements in cancer treatments. Moderna's melanoma vaccine showed promising late-stage trial results, boosting its stock. Revolution Medicines' FDA-approved prostate cancer drug targets previously 'undruggable' mutations. Both treatments are used alongside existing drugs and are not cures but represent breakthroughs in cancer therapy. Investors celebrated the successes, with Moderna's stock surging 177% and Revolution Medicines seeing incr

Moderna's stock (MRNA) has pulled back from recent highs despite a 404% year-to-date gain. The company reported positive phase 3 trial results for its cancer vaccine, intismeran autogene, in collaboration with Merck. Analysts estimate potential peak revenue of $5.6 billion for the vaccine, shared equally with Merck. Moderna also gained FDA approval for its flu vaccine, mFLUSIVA. Despite a high valuation, the company's pipeline and clinical progress make it an attractive long-term investment, acc